Lupin's share price rose in the early trade on July 15 after the company received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility located in Dabhasa, Gujarat.At 09:29 am, Lupin was quoting at Rs 1,813.75, up Rs 16.65, or 0.93 percent, on the BSE.The EIR was issued after the last inspection of the facility conducte...

Here's a quick look at the stocks that will be in focus in trade on Monday, covering quarterly earnings, order wins, and USFDA approvals announced by companies over the weekend:Results TodayHDFC Asset Management Company, HDFC Life Insurance Company, Jio Financial Services, Bank of Maharashtra, Angel One, SpiceJet, Den Networks, Hatsun Agro Product, Atam Valves, Benares Hotels, Davangere Sugar Comp...

Following the patent expiry of Novartis’ blockbuster heart drug on Monday, global pharma major Lupin on Wednesday announced that it has launched the generic version of the combination drug in India.The combination drug Sacubitril and Valsartan will be marketed under two brand names, Valentas and Arnipin.This drug combination is indicated for patients with Heart Failure (HF) conditions. Valenta...

Global pharma major Lupin Limited on Thursday announced the launch of a novel fixed-dose triple drug combination (FDC) of Indacaterol, Glycopyrronium and Mometasone for managing inadequately controlled asthma amongst patients. The company has launched this important product under the brand name DIFIZMA in India.According to the company’s statement, Lupin is the first company in India to offer ...

NSE Nifty 50 index formed a small bodied bearish candle on daily scale with a long upper shadow indicating pressure at higher zones. It has been making lower highs – lower lows from the last six trading sessions. India VIX was up by 2.43% from 21.56 to 22.09 levels on Wednesday. Volatility is hovering at higher zones which is giving discomfort to the bulls. On Options front, Maximum Call OI is a...